Items Tagged ‘clinical trial’

October 12th, 2016

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma

By

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in younger patients with newly diagnosed multiple myeloma (MM). The findings of this trial clearly demonstrated that ASCT should remain the preferred treatment for younger patients with MM. The clinical trial […]

View full entry

Tags: ASCT, bortezomib, clinical trial, cyclophosphamide, dexamethasone, HOVON, Multiple Myeloma, News, Stem Cell Transplant, velcade


August 31st, 2016

Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes

By

The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but are not eligible for erythropoiesis-stimulating agents. These results were recently published in the Journal of Clinical Oncology. Myelodysplastic syndromes (MDS) refer to a group of diseases in which […]

View full entry

Tags: clinical trial, General Myelodysplastic Syndrome, lenalidomide, MDS, Myelodysplastic Syndrome, News, RBC, revlimid


March 29th, 2016

Xalkori® Approved for Lung Cancer with ROS-1 Gene Alterations

By

The United States Food and Drug Administration (FDA) approved Xalkori (crizotinib) as treatment for patients with advanced non-small cell lung cancer (NSCLC) whose cancer has an alteration within the ROS-1 gene. Xalkori is already approved for the treatment of patients with NSCLC that have a mutation in the anaplastic lymphoma kinase (ALK) gene. Lung cancer […]

View full entry

Tags: clinical trial, crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, ROS-1 gene, xalkori


March 15th, 2016

Clinical Study Evaluating Dalantercept in Combination with Axitinib Now Enrolling Advanced RCC Patients Nationwide

By

If you are battling kidney cancer, otherwise known as renal cell carcinoma (RCC), The DART Study may be the next treatment option for you to consider. Dalantercept, in combination with axitinib, an FDA approved therapy, aims to halt the growth and spread of RCC. The DART Study is testing the safety and efficacy of dalantercept in combination with axitinib and is […]

View full entry

Tags: axitinib, clinical trial, dalantercept, DART study, General Renal Cancer, kidney cancer, News, rcc, Renal Cancer, renal cell carcinoma, study


March 9th, 2016

Shorter Radiation Schedule Effective in Low-Risk Prostate Cancer

By

Men with low-grade prostate cancer have the same long-term outcomes when they are treated with a shorter radiation schedule, compared to those treated with a longer, conventional radiation schedule. These results were recently presented at the 2016 annual Genitourinary Cancers Symposium. Low-grade prostate cancer refers to cancer that has not spread to distant sites in […]

View full entry

Tags: clinical trial, hypofractionated, Prostate Cancer, radiation


February 17th, 2016

Immune Therapy for Brain Tumors: A New Promising Avenue

By

  Glioblastoma is a particularly aggressive type of brain cancer. Only about one fifth of adults diagnosed with it survive two years or more after their diagnosis. A new two-drug combination, currently in early clinical trials, might help people diagnosed with glioblastoma to fight the disease. In a presentation of early clinical trial data to […]

View full entry

Tags: Brain Cancer, clinical trial, glioblastoma, immune inhibitor, indoximod, News, temozolomide, UNM CCC


November 4th, 2015

Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy

By

The addition of two years of anti-androgen therapy (AAT) to radiation therapy reduces the risk of death caused by prostate cancer among men treated for a recurrence following a prostatectomy. Treatment for early prostate cancer often includes the surgical removal of the prostate (prostatectomy). Unfortunately, some patients will experience a cancer recurrence following surgery. Treatment […]

View full entry

Tags: anti-androgen therapy, ATT, clinical trial, News, Prostate Cancer, prostatectomy, radiation, recurrence, Refactory/Recurrent Prostate Cancer


October 8th, 2015

Low Oncotype® Recurrence Score® Identifies Group of Women with Early Stage Breast Cancer That can Avoid Chemotherapy

By

The results of a study presented at the European Cancer Congress demonstrate that early-stage breast cancer patients with a low Oncotype DX® Recurrence Score® result of 10 or less who received hormonal therapy alone without chemotherapy had less than a one percent chance of distant recurrence at five years. The results are the first to be […]

View full entry

Tags: Breast Cancer, clinical trial, early-stage breast cancer, News, oncotype dx, Stage I Node Negative Breast Cancer, Tailorx, Trial Assigning Individualized Options for Treatment (Rx)


September 21st, 2015

Varubi Approved for Chemotherapy-Induced Nausea and Vomiting

By

The United States Food and Drug Administration (FDA) approved the agent Varubi (rolapitant) to be used to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of treatment with chemotherapy among cancer patients. It can become a serious side effect in that it can cause dehydration, electrolyte […]

View full entry

Tags: chemotherapy-induced, CINV, clinical trial, nausea, Other News Topics (not Types of Cancer), rolapitant, Varubi, vomiting


September 17th, 2015

Daratumumab Effective in Multiple Myeloma

By

The targeted agent, daratumumab, which is still in clinical trials, appears to be effective in patients with multiple myeloma that has stopped responding to standard therapies. These results were recently published in the New England Journal of Medicine. Multiple myeloma is a cancer of plasma cells, which are a special type of white blood cell […]

View full entry

Tags: clinical trial, daratumumab, Multiple Myeloma, News, Recurrent Multiple Myeloma, refactory


September 14th, 2015

Early Results of Opdivo® Combined with Yervoy® Presented at 16th World Conference on Lung Cancer

By

An early-stage study shows Opdivo® (nivolumab) treatment can be safely and effectively paired with relatively low and infrequent dosages of Yervoy® (ipilimumab) immunotherapy for patients with previously untreated lung cancer, researchers said on Monday at the 16th World Conference on Lung Cancer in Denver, CO. Lung cancer remains the leading cause of cancer-related deaths worldwide. […]

View full entry

Tags: clinical trial, CTLA4, Lung Cancer, Lung Cancer - Non-Small Cell, monoclonal antibody, News, nsclc, opdivo, PD-1 inhibitors, Recurrent Lung Cancer - Non-Small Cell, Yervoy


September 2nd, 2015

Immunotherapy Benefits Patients with Drug-Resistant Multiple Myeloma

By

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine. The drug, daratumumab, proved generally safe in patients even […]

View full entry

Tags: antibody therapy, clinical trial, daratumumab, monoclonal antibody, Multiple Myeloma, News, Recurrent Multiple Myeloma


August 27th, 2015

Breast Cancer Research and Treatment Publishes Oncotype DX(R) DCIS Score(TM) Study Conducted in Canada

By

Genomic Health, Inc. (Nasdaq: GHDX) announced that Breast Cancer Research and Treatment published results from a second large clinical validation study of Oncotype DX® in patients with stage 0 breast cancer, also known as DCIS (Ductal Carcinoma In Situ). The population-based study, conducted by the Ontario DCIS Study Group, reconfirmed that the Oncotype DX DCIS […]

View full entry

Tags: Breast Cancer, Carcinoma In Situ Breast cancer, clinical trial, DCIS, genomic study, News, personalized treatment


July 13th, 2015

Researchers Recruit Herpes Virus as Part of Brain Cancer Treatment

By

A therapy that uses the herpes virus to make tumors more vulnerable to treatment appears promising in the treatment of glioblastoma multiforme (GBM), a form of brain cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical […]

View full entry

Tags: AdV-Tk, Brain Cancer, clinical trial, gbm, Gene Therapy, General Brain Cancer, gliobastoma multiforme, herpes virus, News, treatment


July 1st, 2015

Rintega® Improves Survival in Patients with Glioblastoma Multiforme

By

The immunotherapy drug Rintega® (rindopepimut) appears to improve survival among patients with relapsed glioblastoma multiforme (GBM) brain cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical Oncology. Glioblastoma multiforme is one of the most common and […]

View full entry

Tags: avastin, bevacizumab, Brain Cancer, clinical trial, EGFRvIII, gbm, General Brain Cancer, glioblastoma multiforme brain cancer, News, rindopepimut, Rintega